Johnson & Johnson Forecast, price target & analysts
$253.79
0.69%
NYSE, Oct 19, 04:11 pm EDT.
Closed.
Index
Industry
Johnson & Johnson Target price 2026 - Analyst rating & recommendation
Powered by
Johnson & Johnson Classifications & Recommendation
Buy
71%
Hold
29%
Johnson & Johnson Price Target
| Target Price | $287.64 |
| Price | $253.79 |
| Potential | 13.34% |
| Number of Estimates | 27 |
| 27 Analysts have issued a price target Johnson & Johnson 2027 . The average Johnson & Johnson target price is $287.64. This is 13.34% higher than the current stock price. The highest price target is $336.00 32.39% , the lowest is $171.70 32.35% . | |
| A rating was issued by 31 analysts: 22 Analysts recommend Johnson & Johnson to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Johnson & Johnson stock has an average upside potential 2027 of 13.34% . Most analysts recommend the Johnson & Johnson stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
26 Analysts have issued a sales forecast Johnson & Johnson 2026 . The average Johnson & Johnson sales estimate is
. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .This results in the following potential growth metrics:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
Sign up for free to unlock analyst estimates.
Sign up for free
Powered by
Johnson & Johnson...
Current Johnson & Johnson Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 16 2026 |
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Oct 15 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 14 2026 |
| Leerink Partners |
Outperform
➜
Outperform
|
Unchanged | Oct 14 2026 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Oct 14 2026 |
| Guggenheim |
Buy
➜
Buy
|
Unchanged | Oct 07 2026 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 06 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 16 2026 |
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Oct 15 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 14 2026 |
|
Unchanged
Leerink Partners:
Outperform
➜
Outperform
|
Oct 14 2026 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Oct 14 2026 |
|
Unchanged
Guggenheim:
Buy
➜
Buy
|
Oct 07 2026 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 06 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
